Blue Water Ventures International, Inc. (BWVI)
| Market Cap | 60.56K |
| Revenue | n/a |
| Net Income | n/a |
| Shares Out | 302.79M |
| EPS | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,106 |
| Average Volume | 55 |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 0.0001 - 0.0403 |
| Beta | -19.69 |
| RSI | 71.95 |
| Earnings Date | n/a |
About BWVI
Blue Water Ventures International, Inc., through its subsidiary, Psycheceutical Inc., focuses on developing pharmaceutical products and technologies for mental health treatments. The company was incorporated in 2006 and is based in Fort Lauderdale, Florida. [Read more]
News
Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences
MIAMI, FL / ACCESSWIRE / May 16, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for ...
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
The distress in the psychedelic space contributed to the Company's challenges. The inability of the Company to undertake certain corporate actions (name and symbol change etc.
Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.
MIAMI, FL / ACCESSWIRE / December 12, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies...
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
Company's novel NeuroDirectTM topical ketamine formulation to treat PTSD shown to be safe and well-tolerated in first cohort of Phase I trial. MIAMI, FL / ACCESSWIRE / August 10, 2023 / Psycheceutical...
Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
Multi-year PCAOB audited financials completed Company on the path to become fully SEC reporting Future corporate action with name and symbol change MIAMI, FL / ACCESSWIRE / August 1, 2023 / Psycheceut...
First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD
Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder through the company's NeuroDirect™ delivery system. M...
The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.'s (OTCPK:BWVI) Novel Topical Ketamine Delivery
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side Effects FT. LAUDERDALE, FL / ACCESSWIRE / April 18, 202...
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
Doblin commented on the potential of the company's NeuroDirect™ ketamine topical cream to help those suffering from PTSD Doblin commented on the potential of the company's NeuroDirect™ ketamine topica...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
MIAMI, March 21, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for th...
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
MIAMI, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge technologies for t...
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD Company intends to pursue 505(b)(2) regulatory pathway for novel topical form...
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD) Topical ketamine formulations could improve the methods of treating post-traumatic stress diso...
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
Renowned neurosurgeon to oversee the development of breakthrough psychedelic therapeutics Renowned neurosurgeon to oversee the development of breakthrough psychedelic therapeutics
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company's Scientific Director
Dr. Logsdon's expertise to help guide the company's further research and development for its patented drug-delivery technology Dr. Logsdon's expertise to help guide the company's further research and ...
Psycheceutical Bioscience, Inc. Announces Medical Advisory Board
To be led by accomplished Neurosurgeon Dr. Julian Bailes, the Medical Advisory Board will support the Company in developing breakthrough psychedelic medicine technologies for mental health treatments ...
Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga's Council Board Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will j...
Psycheceutical Bioscience, Inc.'s CEO to Present at the Life Sciences Investor Forum on September 15
Chad Harman, CEO of Psycheceutical, will share an overview of the Company and hold a brief Q&A for the Virtual Forum. Chad Harman, CEO of Psycheceutical, will share an overview of the Company and hold...
Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences
Vici Health Sciences CEO Anish Dhanarajan to join Psycheceutical as Research and Development Advisor Vici Health Sciences CEO Anish Dhanarajan to join Psycheceutical as Research and Development Adviso...
Psycheceutical Brings on Original Shark from 'Shark Tank,' Kevin Harrington, as Investor and Strategic Advisor
Famed entrepreneur excited about the company's development of psychedelic pharmaceutical medicines to treat the widespread mental health crisis MIAMI , May 10, 2022 /PRNewswire/ -- Psycheceutical, In...
Psycheceutical Announces Agreement with Vici Health Sciences
Relationship focused on development of IP and branded formulations MIAMI, March 15, 2022 /PRNewswire/ -- Psycheceutical, Inc. (a wholly-owned subsidiary of Psycheceutical Bioscience, Inc. (OTC: BWVI),...